These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 19686409)

  • 1. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of tumor markers in determining resectability of pancreatic cancer.
    Schlieman MG; Ho HS; Bold RJ
    Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
    Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.
    Zhang S; Wang YM; Sun CD; Lu Y; Wu LQ
    World J Gastroenterol; 2008 Jun; 14(23):3750-3. PubMed ID: 18595144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
    Brown EG; Canter RJ; Bold RJ
    J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.
    Herreros-Villanueva M; Ruiz-Rebollo L; Montes M; Rodriguez-Lopez M; Francisco M; Cubiella J; Iyo E; Garabitos E; Martínez Moneo E; Martos M; de Madaria E; Martínez-Arránz I; García-Cougil M; Iglesias-Gómez A; Bujanda L
    Mol Biol Rep; 2020 Mar; 47(3):1583-1588. PubMed ID: 31915999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
    Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of preoperative CA19-9 levels in evaluating resectability of gallbladder carcinoma.
    Liu F; Wang JK; Ma WJ; Yang Q; Hu HJ; Li FY
    ANZ J Surg; 2019 Mar; 89(3):E76-E80. PubMed ID: 30306702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients.
    Santucci N; Facy O; Ortega-Deballon P; Lequeu JB; Rat P; Rat P
    Pancreatology; 2018 Sep; 18(6):666-670. PubMed ID: 30153902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma.
    Ong SL; Garcea G; Thomasset SC; Mann CD; Neal CP; Abu Amara M; Dennison AR; Berry DP
    J Gastrointest Surg; 2008 Jun; 12(6):1068-73. PubMed ID: 18043987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis.
    van Manen L; Groen JV; Putter H; Vahrmeijer AL; Swijnenburg RJ; Bonsing BA; Mieog JSD
    Biomarkers; 2020 Mar; 25(2):186-193. PubMed ID: 32009482
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Role of Preoperative Serum CA19-9 and Carcinoembryonic Antigen (CEA) Levels in Evaluating the Resectability of Advanced Gallbladder Cancer.
    Ma W; Li W; Wang J; Wu R; Liu C; Feng F; Jiang X
    Med Sci Monit; 2020 Sep; 26():e925017. PubMed ID: 32950997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative Tumor Markers Independently Predict Survival in Stage III Gastric Cancer Patients: Should We Include Tumor Markers in AJCC Staging?
    Lin JX; Wang W; Lin JP; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu R; Zheng CH; Huang CM; Zhou ZW; Li P
    Ann Surg Oncol; 2018 Sep; 25(9):2703-2712. PubMed ID: 29971670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
    Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
    Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.